Tuesday, 9 November 2021 to Wednesday, 10 November 2021
| Bioluminescent Tools & Approaches for RAS Pathway Drug Discovery | |||||
|
Tue9 Nov10:15am(15 mins)
|
|
|
Dr Craig Malcolm | ||
| Session : Keynote Presentation | |||||
| Room: Auditorium | |||||
| An update on the JUMP-CP Consortium: insights from pilot experiments and outlook | |||||
|
Tue9 Nov11:15am(30 mins)
|
|
|
Paula A. Marin-Zapata | ||
| Session : Emerging Discovery Strategies | |||||
| Room: Auditorium | |||||
| R&D at the New Speed of Science - Accelerate your R&D Transformation with Benchling | |||||
|
Tue9 Nov11:45am(5 mins)
|
|
Jonathan Stone | |||
| Session : Emerging Discovery Strategies | |||||
| Room: Auditorium | |||||
| From Theraphosid to Therapy: Screening a venom library using high-throughput automated patch clamp to identify novel and selective sodium channel modulators | |||||
|
Tue9 Nov11:50am(30 mins)
|
|
|
Miss Elaine Duncan |
|
Steven Trim |
| Session : Emerging Discovery Strategies | |||||
| Room: Auditorium | |||||
| Fragment-based screening coupled to chemical proteomics as an emerging paradigm for early drug discovery in ER+ breast cancer | |||||
|
Tue9 Nov02:00pm(30 mins)
|
|
|
Dr Stephanie Constantinou |
|
Dr Aarti Kawatkar |
| Session : Emerging Discovery Strategies | |||||
| Room: Auditorium | |||||
| CDD Vault - Complexity Simplified | |||||
|
Tue9 Nov02:30pm(5 mins)
|
|
|
Miss Tamsin Lamont | ||
| Session : Emerging Discovery Strategies | |||||
| Room: Auditorium | |||||
| The concept of G-quadruplex ligands as novel gene regulators and potential anticancer drugs | |||||
|
Tue9 Nov02:35pm(30 mins)
|
|
|
Stephen Neidle | ||
| Session : Emerging Discovery Strategies | |||||
| Room: Auditorium | |||||
| Right assay, right hit, right time. Identify “more physiological hits” earlier in drug discovery | |||||
|
Tue9 Nov03:35pm(30 mins)
|
|
Mrs Kathy Dodgson | |||
| Session : Emerging Discovery Strategies | |||||
| Room: Auditorium | |||||
| Patient-derived cell models as a clinically-relevant drug discovery strategy | |||||
|
Tue9 Nov04:05pm(30 mins)
|
|
|
Gareth Griffiths | ||
| Session : Emerging Discovery Strategies | |||||
| Room: Auditorium | |||||
| Using DiBT-MS for high throughput and novel biocatalyst pharmaceutical discovery | |||||
|
Wed10 Nov09:10am(50 mins)
|
|
|
Perdita Barran | ||
| Session : Keynote Presentation | |||||
| Room: Auditorium | |||||
| Modernising Drug Design and Prioritisation with AI | |||||
|
Wed10 Nov10:30am(30 mins)
|
|
Simon Richards | |||
| Session : Emerging Discovery Strategies | |||||
| Room: Auditorium | |||||
| Getting started with high-throughput mass spectrometry in early drug discovery | |||||
|
Wed10 Nov11:00am(30 mins)
|
|
Dr Martin Bachman | |||
| Session : Emerging Discovery Strategies | |||||
| Room: Auditorium | |||||
| Development of BromoTag: A “Bump-and-Hole”–PROTAC System to Induce Potent, Rapid, and Selective Degradation of Tagged Target Proteins | |||||
|
Wed10 Nov11:30am(30 mins)
|
|
|
Adam Bond | ||
| Session : Emerging Discovery Strategies | |||||
| Room: Auditorium | |||||
| Accelerating the validation of endogenous on-target engagement and assessment of in-cellulo kinetics for covalent inhibitors in early drug discovery | |||||
|
Wed10 Nov01:30pm(30 mins)
|
|
Dr Vasudev Kantae | |||
| Session : Emerging Discovery Strategies | |||||
| Room: Auditorium | |||||
| New way of screening: A case study comparing an iterative screening approach to conventional HTS campaigns. | |||||
|
Wed10 Nov02:00pm(30 mins)
|
|
|
Markus Hierl | ||
| Session : Emerging Discovery Strategies | |||||
| Room: Auditorium | |||||
| A MALDI-TOF assay identifies nilotinib as an inhibitor of inflammation in acute myeloid leukaemia | |||||
|
Wed10 Nov02:30pm(30 mins)
|
|
|
Prof Matthias Trost | ||
| Session : Emerging Discovery Strategies | |||||
| Room: Auditorium | |||||
